Premium
Screening for Fabry disease and Hereditary ATTR amyloidosis in idiopathic small‐fiber and mixed neuropathy
Author(s) -
Samuelsson Kristin,
Radovic Ana,
Press Rayomand,
Auranen Mari,
Ylikallio Emil,
Tyynismaa Henna,
KäRppä Mikko,
Veteläinen Matilda,
Peltola Niina,
Mellgren Svein Ivar,
Mygland Åse,
Tallaksen Chantal,
Andersen Henning,
Terkelsen Astrid Juhl,
Fontain Freja,
Hietaharju Aki
Publication year - 2019
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.26348
Subject(s) - medicine , fabry disease , amyloidosis , peripheral neuropathy , transthyretin , disease , genetic testing , population , gastroenterology , dermatology , endocrinology , diabetes mellitus , environmental health
ABSTRACT Introduction : In this study we assessed the value of genetic screening for Fabry disease (FD) and hereditary ATTR amyloidosis in patients with idiopathic small‐fiber neuropathy (SFN) or mixed neuropathy in a clinical setting. Methods : This was a Nordic multicenter study with 9 participating centers. Patients with idiopathic SFN or mixed neuropathy were included. Genetic sequencing of the TTR and GLA genes was performed. Results : There were 172 patients enrolled in the study. Genetic screening was performed in 155 patients. No pathogenic mutations in the TTR gene were found. A single patient had a possible pathogenic variant, R118C, in the GLA gene, but clinical investigation showed no firm signs of FD. Discussion : Screening for hereditary ATTR amyloidosis and FD in patients with idiopathic SFN or mixed neuropathy without any additional disease‐specific symptoms or clinical characteristics in a Nordic population appears to be of little value in a clinical setting. Muscle Nerve 59 :354–357, 2019